23andMe Holding Co. announced the appointment of Joseph R. Arron, M.D., Ph.D., as the company?s new Chief Scientific Officer. In this role, Dr. Arron will determine and prioritize 23andMe?s therapeutic programs and indications, including drug discovery and target validation efforts, and build out a pipeline that yields clinical stage programs. Dr. Arron will report to Kenneth Hillan, Head of Therapeutics at 23andMe. Dr. Arron previously served as Vice President and Senior Fellow, Immunology Research at Genentech. Dr. Arron joined Genentech in 2006, where his laboratory discovered pathogenic mechanisms and molecular bases for heterogeneity in respiratory disorders, enabling target and biomarker discovery for numerous investigational molecular therapies that resulted in over 75 publications.